On the 9th, the National Medical Products Administration conducted a management review of the 2024 vaccine supervision and drug production inspection quality management system (vaccine QMS and drug production inspection QMS).

Li Li, Secretary of the Party Leadership Group and Director of the State Drug Administration, pointed out that the State Drug Administration has continued to deepen the effective operation of the vaccine QMS, coordinated and promoted the smooth start of the drug production inspection QMS, fully utilized the role of the quality management system in monitoring and reviewing the entire process, and continuously improved the work related to drug supervision. The vaccine QMS and drug production inspection QMS of the State Drug Administration are appropriate, sufficient and effective, and the work has achieved remarkable results. Through the hierarchical and classified management of drug inspectors, high-level training of drug inspectors, and the training of a group of backbone inspectors with international standards, the capacity of regulatory personnel has been continuously enhanced. The relevant departments and bureaus have conscientiously implemented the quality management concept, adhered to the whole process quality management, regularly conducted risk consultations, and continuously and efficiently carried out internal audit work to promote drug supervision work to be more compliant and orderly.

https://finance.eastmoney.com/a/202506103426605333.html